News

OR Royalties Inc. Sees Strong Profit in Q2 2025 Results

OR Royalties Inc. Sees Strong Profit in Q2 2025 Results

Financial Summary of Q2 2025

MONTRÉAL, OR Royalties Inc. (“OR Royalties” or the “Company”) (TSX: OR, NYSE: OR) has released its consolidated financial results for the second quarter of 2025. Presenting impressive figures, the Company has showcased substantial growth opportunities in the mining sector, specifically in royalties and streams.

Key Achievements

During the quarter, OR Royalties earned 19,700 gold equivalent ounces (GEOs), compared to 20,068 GEOs in the same period last year. This demonstrates the company's robust operational efficiency, despite minor fluctuations in production levels.

  • The royal and stream revenue saw a sharp rise to $60.4 million, a 27% increase from $47.4 million in Q2 2024.
  • Cash flow generated by operations was approximately $51.4 million, showing notable growth from $38.2 million in the previous year.
  • The net earnings stood at $32.4 million, translating to $0.17 per basic share, compared to a loss recorded at $15.4 million or $0.08 per basic share in Q2 2024.
  • Adjusted earnings reached $34.1 million or $0.18 per share, indicating a positive trajectory against $24.2 million or $0.13 per share from the previous year.
  • Net repayments under the revolving credit facility amounted to $40.0 million, demonstrating strategic financial management.
  • The Company maintained a healthy cash balance of $49.6 million, with outstanding debt totaling $35.7 million as of June 30, 2025.
  • Increased the revolving credit facility to $650 million plus an uncommitted accordion of $200 million, extending the maturity to May 30, 2029.
  • Achieved its first royalty payments from Cardinal Namdini Mining Ltd. and Talisker Resources Ltd., adding new revenue streams to its portfolio.
  • Completed the acquisition of a silver stream on Orla Mining Ltd.'s South Railroad project for $13 million.
  • Acquired a basket of royalties across British Columbia for $2.8 million from Sable Resources Ltd., expanding its royalty interests.
  • Conducted a successful corporate name change to “OR Royalties Inc.” following shareholder approval.
  • Published the fifth edition of its sustainability report, highlighting its commitment to responsible growth.
  • Declared a quarterly dividend of $0.055 per share, marking a 20% increase from prior distributions.

Looking Ahead

Looking forward, OR Royalties is on track to meet its annual guidance of 80,000 to 88,000 GEOs for the year. The second half of 2025 is set to be stronger based on the expected operational ramp-up across its asset portfolio, including key contributors such as Canadian Malartic and Mantos Blancos.

Management Remarks

Jason Attew, President & CEO, expressed optimism regarding the Company’s future: “We are pleased with our progress and anticipate a strong end to the year, with various catalysts in our portfolio including feasibility studies and expansion projects.” Attew added that OR Royalties is in a net-cash position, enhancing its capability for growth initiatives in the coming years.

Next Steps

The Company encourages its shareholders and investors to participate in the upcoming earnings conference call scheduled for August 6, 2025. Further details will be released closer to the date.

About OR Royalties Inc.

As a leading precious metals royalty and streaming enterprise, OR Royalties focuses on Tier-1 mining jurisdictions, primarily Canada, the USA, and Australia. Starting with a single producing asset in 2014, it has expanded to hold over 195 royalties and streams, significantly enhancing its market presence.

Frequently Asked Questions

What were the key financial results for OR Royalties in Q2 2025?

OR Royalties reported revenues of $60.4 million and net earnings of $32.4 million or $0.17 per share for Q2 2025.

How did the royalty payments impact OR Royalties' financial position?

The receipt of royalty payments from Cardinal Namdini Mining and Talisker Resources significantly contributed to the overall revenue growth in Q2 2025.

What is the future outlook for OR Royalties?

The Company is on track to meet its annual guidance of 80,000 to 88,000 GEOs, with further growth anticipated in the second half of the year.

What strategies is OR Royalties employing for growth?

OR Royalties plans to leverage its enhanced cash position and expanded credit facility to pursue further royalty acquisitions and growth opportunities.

How can investors keep updated on OR Royalties’ performance?

Investors can join the upcoming conference call on August 6, 2025, for the latest insights and updates directly from management.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading